Welcome to our dedicated page for Cibus SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cibus, Inc.'s SEC filings document an agricultural biotechnology company that uses proprietary gene-editing technologies to develop plant traits for licensing to seed companies. The filings describe its royalty-oriented model, productivity traits for major agricultural food crops, and trait categories tied to weeds, pests, diseases, sustainability and yield challenges.
The company's regulatory record includes 8-K material-event reports, financial-results exhibits, proxy materials, governance disclosures and capital-structure information for its Class A common stock. These filings also cover board appointments, compensatory arrangements, shareholder voting matters, material agreements, registered securities and business disclosures related to the development and commercialization of gene-edited crop traits.
Cibus, Inc. plans an underwritten public offering of Class A common stock on Nasdaq to raise cash for operations and its rice weed-management trait programs. Board members may buy up to approximately $1.5 million of shares at the public price, and BTIG is the sole bookrunner with a 30‑day option to purchase additional shares.
Cibus highlights significant going concern risks. As of September 30, 2025, it held $23.9 million in cash and cash equivalents against $20.6 million in current liabilities, and it is targeting annual net cash usage of about $30 million or less during 2026 after restructuring and workforce reductions.
The company is focusing capital on herbicide-tolerant rice traits, which management believes could ultimately support annual accessible royalties of over $200 million in initial markets, while pursuing partner-funded programs in biofragrances and lauric oils. A special board committee is exploring strategic alternatives, including financings, business combinations, asset sales and licensing, and warns that failure to secure sufficient capital could lead to a wind-down in which shareholders may lose most or all of their investment.
Cibus, Inc. (CBUS) reported an equity award to a company director. On 11/05/2025, the director received a stock option to buy 45,627 shares of Class A common stock at an exercise price of $1.32 per share. The option becomes exercisable on 05/22/2026 and expires on 11/05/2035, with no purchase price paid for the option itself. Following this grant, the director beneficially owns 45,627 derivative securities directly.
The option vests, subject to continued board service, on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting. Any remaining unvested portion will fully vest if a defined Triggering Event under the company’s 2017 Omnibus Incentive Plan occurs while the director continues to serve.
Cibus, Inc. filed an initial ownership report for director Craig Wichner. The Form 3 indicates that, as of the event date of 11/05/2025, he beneficially owns 0 shares of Cibus Class A Common Stock in direct form. The filing also shows no reportable derivative securities, meaning there are no listed options, warrants, or other convertible instruments tied to Cibus stock for this reporting person at this time.
Cibus, Inc. filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Revenue was $615 thousand for the quarter and $2.6 million year‑to‑date, reflecting limited current commercialization. Quarterly net loss was $24.3 million; year‑to‑date net loss was $100.3 million.
Cash and cash equivalents were $23.9 million as of September 30, 2025, against $20.6 million in current liabilities. Management states that additional capital will be needed within a year to support plans. The company raised net proceeds of approximately $21.4 million in January 2025 and $25.0 million in June 2025 follow‑on offerings and terminated its prior ATM facility without 2025 sales.
Year‑to‑date operating expenses totaled $77.5 million, including a $20.9 million goodwill impairment recognized in Q1. A July workforce reduction of ~34 roles incurred $0.2 million in severance in Q3. As of November 10, 2025, the company reported 54,283,111 shares outstanding across Class A and Class B.
Cibus, Inc. reported its results for the three months ended September 30, 2025 and provided a year‑to‑date business update. The company furnished a press release with details as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under the Exchange Act, limiting its use for liability purposes unless specifically incorporated by reference. The report was signed by Interim Chief Executive Officer Peter Beetham on November 13, 2025.
Cibus, Inc. (CBUS) appointed Craig Wichner to its Board of Directors, effective November 5, 2025, and named him to the Board’s Strategy Committee.
Wichner is the Founder and Managing Partner of Farmland LP, a U.S. farmland investment manager with more than $350 million in assets and over 19,000 acres under management. His annual director compensation includes a $60,000 cash retainer (payable semi-annually) and equity with a grant date value of $90,000, prorated for the remainder of fiscal 2025, subject to Board approval under the company’s 2017 Omnibus Incentive Plan. He also entered into the company’s standard indemnification agreement.
Kimberly A. Box, a director of Cibus, Inc. (CBUS), was granted a stock option on 09/11/2025 to purchase 54,722 shares of Class A common stock at an exercise price of $1.40 per share. The option vests on the earlier of the first anniversary of the grant date or the company’s next annual shareholders meeting, subject to continued service, and becomes exercisable beginning 09/11/2026 with an expiration date of 09/11/2035. The filing reports direct beneficial ownership of 54,722 shares following the grant. The grant includes standard acceleration on a defined Triggering Event per the company’s 2017 Omnibus Incentive Plan.
Cibus, Inc. (CBUS) Form 3 filed by Kimberly A. Box discloses her role as a director and reports zero shares of Class A common stock and no derivative securities as of the 09/11/2025 event date. The filing is an initial beneficial-ownership statement and was signed by an attorney-in-fact on 09/26/2025. The disclosure documents the absence of direct equity holdings by this reporting director.
Cibus, Inc. disclosed an Executive Employment Agreement appointing Cornelis (Carlo) Broos as Chief Financial Officer effective September 18, 2025 (agreement dated September 19, 2025). The agreement is at-will but provides severance protections: 18 months of continued base salary if the company terminates him without Cause or he leaves for Good Reason; and enhanced 24-month severance plus a lump-sum bonus equal to his target annual bonus (or a projected portion if termination occurs in the second half of the fiscal year) and full vesting of unvested equity if termination happens in connection with a Change in Control. Severance payments require customary release delivery. For tax efficiency, about half of Mr. Broos’ compensation will be paid to a Belgian entity wholly owned by him. The filing notes no family relationships or other arrangements related to the appointment.
Cibus, Inc. notified the appointment and compensation terms for non-employee director Ms. Box. The Board adopted a Non-Employee Director Compensation Policy providing Ms. Box an annual cash retainer of $60,000 payable semi-annually and equity compensation with a grant-date value of $90,000 to be issued under the Cibus, Inc. 2017 Omnibus Incentive Plan, as amended. The award will be prorated to reflect Ms. Box's service for the remainder of the 2025 fiscal year. The filing is signed by Peter Beetham, Ph.D., Interim Chief Executive Officer.